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ABSTRACT
Gastrointestinal bleeding of obscure origin or with an intractable 
cause is particularly common in patients with atrial fibrillation subject 
to oral anticoagulant therapy. This condition is highly recurrent 
and therefore gives rise to high morbidity and mortality rates, thus 
entailing a vicious cycle that is difficult to solve.
Percutaneous left atrial appendage closure has become a 
therapeutic alternative for patients with atrial fibrillation and a 
contraindication for oral anticoagulation. This technique would 
allow the discontinuation of oral anticoagulants, thus helping to 
reduce the risk for gastrointestinal bleeding, and would also be 
protective against embolic events in this group of patients, thereby 
eventually breaking this vicious cycle.
We report our experience with percutaneous left atrial appendage 
closure in the management of patients with atrial fibrillation who 
are subject to oral anticoagulation therapy and suffer from obscure 
or intractable gastrointestinal bleeding.
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INTRODUCTION
Obscure gastrointestinal bleeding (OGIB) is a condition 
clustering together all gastrointestinal bleedings (GIBs) 
secondary to causes that cannot be pinned down following 
attentive endoscopic and radiographic examinations (1). It 
is a condition particularly common in patients subject to 
therapy with oral anticoagulants (OACs) (1,2).
The management of patients with atrial fibrillation (AF) 
and high embolic risk who develop GIB and require treat-
ment with OACs is not well established. The most com-
mon practice involves the performance of a comprehensive 
GI tract examination to elucidate the underlying disease 
and provide an appropriate etiologic therapy. OACs are 
usually reintroduced following stabilization; however, in 
a high percentage of patients relapse rates are high, either 
because no clear cause for GIB can be found or because 
its origin cannot be fully treated (e.g., when multifocal 
angiodysplasia is present) (2,3). Furthermore, relapsing 
bleeding results in multiple hospitalizations and is associ-
ated with high morbidity and mortality (2,4).
The primary origin of embolic events in patients with 
AF is the left atrial appendage (LAA) (5,6). It is for this 
reason that the percutaneous closure thereof together with 
OAC withdrawal may be considered an alternative thera-
peutic approach as it is protective against embolic events 
and concurrently decreases the risk for GIB. Several stud-
ies involving a number of devices are witness to this (6-9).
The goal of our paper is to describe our experience with 
percutaneous LAA closure using a device approved by reg-
ulatory authorities (“CE mark”) for the management of this 
group of patients -the AmplatzerTM Cardiac Plug (ACP) 
device (Saint Jude Medical, St. Paul, USA). 
CASE REPORTS
Between February 2012 and January 2013 four patients 
were selected to undergo percutaneous LAA closure 
using the ACP device after signing their informed consent 
according to a protocol previously established in our site. 
All four patients exhibited well-controlled anticoagulation 
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levels, and all had undergone multiple admissions requir-
ing multiple transfusions. All were subjected to a compre-
hensive etiologic study including fiber gastroscopy, fiber 
colonoscopy, and capsule endoscopy on one or several 
occasions. Also, the patients were not considered eligible 
for treatment with lanreotide or thalidomide for the man-
agement of recurrent GIB.
Case report 1 was an 82-year-old woman with a history 
of high blood pressure (HBP), diabetes mellitus (DM), dys-
lipidemia, aortic valve replacement with a biological pros-
thesis, chronic iron-deficiency anemia, and AF with high 
embolic risk. The patient had a high AF-related embolic 
risk score (CHA2DS2VASc score: 5). The etiologic study 
demonstrated angiodysplasia lesions in the stomach, duode-
num, and mid/distal jejunum that required repeated argon-
beam applications, despite which GIB events persisted and 
made hospital admission necessary on four occasions.
Case 2 report was a 79-year-old woman with a history of 
HBP, DM, dyslipidemia, peripheral vasculopathy, chronic 
iron-deficiency anemia, and AF with high embolic risk 
(CHA2DS2VASc score: 6). Capsule endoscopy demonstrat-
ed multiple angiodysplasia lesions (duodenum, proximal 
jejunum, distal ileum) which resulted in persistent GIB 
despite multiple argon beam sessions. The patient required 
hospitalization for bleeding events on three occasions.
Case 3 was a 69-year-old male with a history of HBP, 
DM, dyslipidemia, mitral valve replacement with a bio-
logical prosthesis, chronic iron-deficiency anemia, and 
AF with high embolic risk (CHA2DS2VASc score: 3). An 
etiologic study revealed no specific origin for his bleeding 
during the two hospitalizations the patient required.
Case 4 was an 86-year-old woman with a history of 
HBP, dyslipidemia, cerebrovascular accident (CVA) with 
resolution ad integrum, ischemic heart disease, peripheral 
vasculopathy, chronic iron-deficiency anemia, and AF with 
high embolic risk (CHA2DS2VASc score: 7). The patient 
required admission to hospital on three occasions but diag-
nostic studies could not reveal the origin of GIB.
All patients had OACs withdrawn three days before 
implantation. The procedure was performed using general 
anesthesia, with prophylaxis against bacterial endocarditis, 
and under trans-esophageal echocardiographic (TEE) and 
angiographic control. Using a right femoral venous access 
a trans-septal puncture kit was advanced into de right 
atrium, following which complete unfractionated heparin 
(UFH) doses were administered with patient body weight 
adjustment. Subsequently the device delivery sheath was 
advanced into the left atrium, and the ACP device was 
implanted, completely covering the LAA ostium in all cas-
es in a stable manner, with no evidence of device migration 
and no complications (Fig. 1 A-D).
All patients were discharged on an indefinite aspirin 
regimen, clopidogrel for 3 months, and proton pump 
inhibitors. In addition, prophylaxis was administered per 
protocol against bacterial endocarditis for 6 months after 
device implantation in the presence of any risky instrumen-
tation. A stringent echocardiographic follow-up protocol 
was implemented (using TEE on discharge and at 30 days, 
3 months and 6 months, and trans-thoracic echocardiog-
raphy at 12 months). Clopidogrel was withdrawn in the 
absence of device-related thrombosis on TEE at 3 months, 
except for case number 2. In this patient mild thrombo-
sis was seen associated with the ACP device on TEE at 
3 months, which required two weeks of inpatient therapy 
with intravenous UFH that eventually solved the problem. 
The patient then continued on clopidogrel until the TEE 
examination at month 6, which confirmed the absence of 
device-associated thrombosis and allowed withdrawal of 
clopidogrel. This patient had no complications related to 
device-associated thrombosis. Furthermore, no other com-
plications were seen in association with implanted devices 
in the remaining echocardiographic controls.
After a mean follow-up of 9.3 ± 3.2 months, patients 
remain asymptomatic and have required no additional 
admissions for GIB; also, they have had neither ischemic, 
hemorrhagic stroke or infectious endocarditis events, nor 
any procedure-related complications.
Fig. 1. Percutaneous implantation of the AmplatzerTM Cardiac Plug 
device for left atrial appendage (LAA) closure. A. The delivery sheath 
is advanced into the LAA. B. Procedure to release the self-expanding 
closure device within the LAA. C. The AmplatzerTM Cardiac Plug is 
appropriately released in the LAA. D. Control angiogram showing the 
appropriately placed AmplatzerTM Cardiac Plug device, now occluding 
the ostium of the LAA with minimal passage of contrast medium into 
the LAA.
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DISCUSSION
The OGIB concept includes all GIB events with an 
unknown cause despite comprehensive endoscopic and 
radiographic testing including capsule endoscopy to assess 
the small bowel (1,10). Furthermore, capsule endoscopy 
is the only tool that can explore the whole GI tract in all 
its length, and discover smaller bleeding lesions such as 
angiodysplasia, which represents one of the most prevalent 
causes of OGIB (10).
AF is the most common tye of sustained arrhythmia and 
also represents a major public health issue. Its prevalence 
increases with comorbidity and age, and may reach 5-15 % 
amongst the population older than 80 years of age (5). In 
addition, this problem will be more severe in the future as 
estimates anticipate prevalence twice as high within the 
next 50 years because of population ageing (5). 
 The most commonly feared complication of AF is arte-
rial thromboembolism in association with blood stagnation 
inside the LAA, which represents over 90 % of emboli in 
these individuals (5,6). CVAs occurring in the context of 
AF are usually fatal, and surviving patients have severely 
impaired cognitive functions and quality of life (5).
The primary preventive therapy available is antico-
agulation. In order to stratify the risk for CVAs among 
patients with valve-unrelated AF the CHA2DS2VASc score 
was devised. This embolic risk score assigns 1 point to 
the presence of heart failure, HBP, DM, arterial vascu-
lopathy, female gender, and age between 65 and 74 years, 
and 2 points to age ≥ 75 years and a history of previous 
CVAs. The European Society of Cardiology guidelines (5) 
recommend OAC initiation in patients with a mid-to-high 
embolic risk (CHA2DS2VASc score ≥ 2).
However, in contrast with OAC benefits, patients with 
AF subject to OAC have a high risk of bleeding because 
of their anticoagulation effects. Also, the most common 
source of bleeding in these subjects has been found to 
be the GI tract (2-4), which may be responsible of up to 
40 % of all bleeding events. Furthermore, severe bleeding 
requiring hospitalization is associated with high inpatient 
mortality and relapse rates (2, 4). 
Given the prognostic significance of bleeding in this 
population, assessing bleeding risk should be an integral 
part of the evaluation prior to OAC onset. This is why the 
HAS-BLED bleeding risk score was designed for patients 
receiving OACs. This score assigns 1 point to HBP, abnor-
mal renal function, abnormal liver functional, CVA, history 
of or predisposition to bleeding, international normalized 
ratio (INR) lability, age > 65 years, concomitant use of 
other antithrombotic agents, and alcohol abuse. A HAS-
BLED score ≥ 3 confers a high bleeding risk and requires 
more careful monitoring of INR values (5).
It is relevant to point out that both scores share a num-
ber of items, hence it is no wonder that patients with high 
CHA2DS2VASc scores also have high HAS-BLED scores, 
and vice versa. Because of this, it is precisely patients with 
a higher risk for embolic events that also have a higher risk 
for bleeding (11).
Given that this group of patients has a highly increased 
embolic risk, the strategy of withdrawing OACs for 
patients with AF having suffered from bleeding episodes 
would expose them to a too high risk for embolism and 
should not therefore be used. The fact that newer anti-
coagulants have not solved this quandary should also be 
highlighted here, as the prevalence of GIB with these 
drugs (e.g., dabigatran) has been seen to be the same 
or even higher than with traditional OACs (Sintrom®) 
(5, 12).
There is, therefore, a group of patients with high embol-
ic risk and a concurrent high risk for GIB for whom there 
was no effective, safe treatment. Since the most common 
source of embolism in patients with AF is the LAA, its per-
cutaneous closure together with OAC withdrawal seems 
an appealing strategy for these patients and offers a dual 
benefit: a) Avoidance of new GIB events; and b) protection 
against embolic episodes. 
Our short, prospective case series of patients undergoing 
percutaneous LAA closure using the ACP device showed 
that the vicious cycle of OGIB may be broken with this 
new endovascular therapy, which prevents readmission for 
GIB and at the same time protects patients against embolic 
events. These fine initial results suggest that our strategy 
(Fig. 2) may be appropriate in this clinical setting, and 
deserves further confirmation by future clinical trials.
A number of studies have shown the feasibility of 
implantation, and the efficacy and safety of the various 
devices intended for LAA closure (6-9); however, none 
was performed in this specific group of patients. The ELI-
GIBLE study (NCT01628068), currently ongoing, will be 
the first trial to specifically assess the effectiveness and 
safety of percutaneous LAA closure in this type of patients. 
This study will shed light on the most appropriate manage-
ment for this population.
Fig. 2. The vicious cycle of obscure or intractable gastrointestinal bleeding 
in a patient with atrial fibrillation receiving oral anticoagulants (AF: Atrial 
fibrillation; OAC: Oral anticoagulant; LAA: Left atrial appendage).
Unknown or intractable cause
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In conclusion, obscure or intractable GI bleeding in 
patients with AF on OACs is a major cause of morbidity 
and mortality, and its management is complex. Percutane-
ous LAA closure and OAC discontinuation may well be an 
optimal therapeutic option to protect patients against both 
GIB and arterial embolism. 
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